ArticleResearch square2026
EMT and cell cycle control invadopodia and metastasis in breast cancer via Filip1L.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Invadopodia are actin- and protease-rich membrane structures that enable cancer cells to degrade extracellular matrix (ECM). Invadopodia activity is cell cycle-dependent, but how their regulation across the cell cycle is influenced by epithelial-to-mesenchymal transition (EMT) remains unclear. We show that as the EMT progresses, cell engagement in invadopodia-mediated ECM degradation shits from G2 phase in Early E/M cells to G1 phase in Late E/M or M cells. Using bulk mRNA sequencing of Early- versus Late-E/M cells sorted by cell cycle phase, we identified FILIP1L as an EMT- and cell cycle-regulated candidate whose expression peaks in the invasive phase of each cell state: G2 in Early E/M cells and G1 in Late E/M cells. We next demonstrated that FILIP1L is a novel invadopodia component, whose loss increases ECM degradation while impairing migration and 3D invasion. In mouse models, FILIP1L KD tumors develop fewer metastatic colonies, suggesting that FILIP1L supports productive invasion by coordinating between invadopodia and migratory cell states. FILIP1L expression increases with EMT progression and correlates with poor outcomes in breast cancer patients. Together, these findings identify a previously unrecognized link between EMT, cell cycle and invadopodia and establish FILIP1L as the key regulator of this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.